Related Experiment Video
Updated: Mar 29, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
p53 as an Effector or Inhibitor of Therapy Response
Julien Ablain1, Brigitte Poirot2, Cécile Esnault1
1Université Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Hôpital St. Louis, 75475 Paris, France INSERM UMR 944, Equipe Labellisée par la Ligue Nationale contre le Cancer, Hôpital St. Louis, 75475 Paris, France CNRS UMR 7212, Hôpital St. Louis, 75475 Paris, France.
Abstract:
Although integrity of the p53 signaling pathway in a given tumor was expected to be a critical determinant of response to therapies, most clinical studies failed to link p53 status and treatment outcome. Here, we present two opposite situations: one in which p53 is an essential effector of cure by targeted leukemia therapies and another one in advanced breast cancers in which p53 inactivation is required for the clinical efficacy of dose-dense chemotherapy. If p53 promotes or blocks therapy response, therapies must be tailored on its status in individual tumors.
Insights
The p53 signaling pathway
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The p53 signaling pathway is crucial in tumor suppression.
- Its role in predicting treatment response has been inconsistent in clinical studies.
- Understanding p53's function in therapy is vital for personalized medicine.
Purpose of the Study:
- To investigate the dual role of the p53 signaling pathway in treatment response.
- To determine if p53 activation or inactivation influences therapeutic outcomes in different cancers.
- To highlight the need for tailoring therapies based on individual tumor p53 status.
Main Methods:
- Comparative analysis of p53 status in leukemia and breast cancer patient cohorts.
- Evaluation of targeted therapy efficacy in leukemia models with intact p53.
- Assessment of dose-dense chemotherapy outcomes in advanced breast cancer with p53 inactivation.
Main Results:
- p53 is essential for cure in targeted leukemia therapies.
- p53 inactivation is required for the efficacy of dose-dense chemotherapy in advanced breast cancers.
- Demonstrated opposing roles of p53 in mediating treatment response.
Conclusions:
- The p53 signaling pathway's role in cancer therapy is context-dependent.
- Therapeutic strategies must be personalized according to the p53 status of individual tumors.
- Tailoring treatments based on p53 can optimize clinical outcomes.
More Related Videos
09:32Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
Published on: September 10, 2017
04:56Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies
There are several types of targeted therapies against...